Status: Not yet recruiting
A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD)
This is a multi-centre, single- arm, non-randomized, open-label phase 1/2 clinical trial which enables dosing of the fellow eyes of patients who received VGR-R01 administration in previous studies.
Participants needed: 15
Trial details
Phase: Phase 1, Phase 2Age: 18-69Biological sex: AllType: InterventionalSponsor: Shanghai Vitalgen BioPharma Co., Ltd.Updated: May 14, 2026Locations: 2
Eligibility criteria
Participants received VGR-R01 administration in the VGR-R01-001 or VGR-R01-101 s... [+2]
Have insufficient viable retinal photoreceptor cells based on investigator's dec... [+8]